Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 5;15:1744806919837429. doi: 10.1177/1744806919837429

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — (a) PDHK inhibitor, DCA (IP 100 mg/kg), reversed bortezomib-induced allodynia on day 10 (bortezomib vs. vehicle ^###P < 0.0001, bortezomib →vehicle vs. bortezomib→DCA ****P < 0.0001, five mice/group). (b) Intrathecal (IT) administration of siRNA that targets PDHK1 reversed bortezomib-induced CIPN (Bor vs. Veh ^###P < 0.0001, Bor → IT PDHK1 siRNA and Bor → IT Cont siRNA ****P < 0.0001, five mice/group). (c) Knockdown of PDHK1 in L4-6 DRGs was confirmed (*P = 0.02, ***P = 0.0002, five mice/group). (d) Intrathecal siRNA administration did not alter the expression of PDHK1 in the L4-6 spinal cord. Veh: vehicle; Bor: bortezomib; DCA: dichloroacetate; BL: baseline IT: intrathecal; Cont: control; PDHK1: pyruvate dehydrogenase kinase 1.